Eurostars
VC Fund
Brussels, Belgium
Eurostars is a VC fund in Brussels focused on Biotechnology and Health Care. This programme is a European Joint Programme dedicated to stimulating R&D performing SMEs.
- Total investments:
- 62
- Last investment:
- Lead investor:
- 84%
Last updated:
For AI agents: llms.txt
Industries Eurostars invests in
Stages Eurostars invests in
Countries Eurostars invests in
Round sizes
Round size
- Grant
- $457k–$2.6M
Investment Focus
Industry
- Biotechnology 26 (42%)
- Health Care 18 (29%)
- Medical 15 (24%)
- Pharmaceutical 11 (18%)
- Medical Device 10 (16%)
Stage
- Grant 56 (90%)
- Seed 1 (2%)
- Pre-Seed 1 (2%)
- Series A 1 (2%)
- Funding Round 1 (2%)
Country
- Switzerland 16 (26%)
- Sweden 9 (15%)
- Denmark 6 (10%)
- The Netherlands 6 (10%)
- United States 5 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
MastCURe
|
MastCURe is a research consortium. | $1.5M / Grant / Apr 17, 2026 | |
Terapet
|
Terapet was founded at CERN by two physicists – Christina Vallgren and Marcus Palm – along with Professor Raymond Miralbell from the Geneva University Hospitals (HUG). They have already proven the feasibility of their concept and are now developing an initial version for market launch. | $2.6M / Grant / Apr 10, 2026 | |
Polar Light Technologies
|
Polar Light Technologies focuses on developing the next generation of Nano and micro LED technology. | Grant / Mar 16, 2026 | |
InVirtuoLabs
|
InVirtuoLabs is a firm that uses artificial intelligence and molecular simulations to transform drug discovery. Their technology identifies and optimizes drug candidates by combining machine learning approaches including multimodal learning, active learning, and generative chemistry with physics-based simulations. | $2.7M / Grant / Feb 11, 2026 | |
Wenemea
|
Wenemea is the developer of chemotherapy-induced peripheral neuropathy designed for cancer treatment through neurological screening. | $1.1M / Grant / Jan 21, 2026 | |
Bio-Sourcing
|
BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global Unmet Medical Needs : Available, Affordable, Sustainable. BioSourcing changes the design paradigm of these new biotherapeutics thanks to the mastery of several breakthrough technologies including genome editing (CRISPR). The BioSourcingdisruptive approach leads to a drastic reduction in capital requirements and production costs, especially for large volumes, as well as an improvement in the quality/efficiency of biopharmaceuticals through better glycosylation. BioSourcing strongly contributes to sustainable development, in particular in drasticly reducing the carbon footprint. BioSourcing is a fully operational biotechnology company, based in Liège, Belgium. Its team is made up of the best scientists, international experts in their field and has developed strategic partnerships with leaders in the pharmaceutical and biotechnology industry. | Grant / Jan 12, 2026 | |
Zerion Pharma
|
Zerion Pharma is a pharmaceutical company that aims to transform the pharmaceutical landscape with a new formulation technology. The company is focused on improving existing drugs by building an internal pipeline to solve the most challenging drug solubility problems that pharmaceutical companies face. Zerion Pharma was founded in 2019 and isbased in Birkerød, Denmark. | Grant / Jan 12, 2026 | |
Broken String Biosciences
|
Broken String Biosciences is developing a platform of novel sequencing tools to assess genome stability and to unlock the next generation of innovative medicines, including cell and gene therapies. | Grant / Jul 10, 2025 | |
Simularge
|
Simularge is a deep-tech company pioneering AI-powered digital twins for industrial manufacturing. Our technology combines domain-specific physics models with deep learning to deliver real-time insights, process optimization, and predictive analytics for high-temperature operations such as thermoforming, injection molding, glass tempering, andmetal processing. Headquartered in Türkiye and the United States, Simularge serves global manufacturers with plug-and-play digital twin solutions that integrate directly with factory PLCs, enabling rapid deployment and ROI. Our proprietary engine captures the nuances of thermal physics, material behavior, and production dynamics to help reduce scrap, lower energy consumption, and improve overall equipment efficiency (OEE). Founded by PhDs in mechanical and computer engineering, Simularge is backed by institutional investors including SSTEK and the Turkish Development Fund, and is a portfolio company of the Alchemist Accelerator (San Francisco). Notable partners and pilot customers include Beko, Vestel, and participants of EU Horizon projects such as Siemens, Fiat, and Ford. Simularge’s mission is to transform industrial intelligence by embedding real-time decision-making into the heart of production. | $472.2K / Grant / Jul 01, 2025 | |
OLS OMNI Life Science
|
OLS OMNI Life Science provides solutions in 3D cell culture, cell counting, cell assays, cell imaging, and microbiology. | Grant / Apr 25, 2025 | |
| See all 62 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Eurostars invest in?
Eurostars invests primarily in Biotechnology, Health Care and Medical startups, most often at Grant and Seed stage. Most of the 62 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Eurostars's check size?
Eurostars typically joins rounds of $457k–$2.6M at Grant. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eurostars participates in.
When did Eurostars last invest?
The most recent investment recorded for Eurostars closed in Apr 2026. Shizune tracks 62 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
